Advicenne to present eight posters on the positive results of ADV7103 in the treatment of rare nephrological diseases at major international conferences
September 3, 2019
Advicenne (Euronext Paris & Brussels: ADVIC – FR0013296746), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare disease, announces its participation in the Pan European Small / Mid Cap conference organized by J.P. Morgan on 10-12 September 2019 in London, United Kingdom. The format of this event offers a selection of approximately 90 European listed companies to meet investors specialized in Small and Mid Caps.